Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 2007-2014

  Seo, Jin Hee ^a   Jeong, Eui Suk ^a   Lee, Kyoung Sun ^a,b   Heo, Seung Ho ^a,c   Jeong, Dong Gu ^a   Choi, Yang Kyu ^a  

^a Konkuk University   (South Korea)

^b Osong Medical Innovation Foundation   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Cyclin D1; Gastric cancer; shRNA

Indexed keywords

CYCLIN D1; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; SHORT HAIRPIN RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; CHEMOSENSITIVITY; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LENTIVIRINAE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LENTIVIRUS; NF-KAPPA B; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 84891943342     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2119     Document Type: Article

References (40)

1. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ and Asia Pacific Working Group on Gastric C: Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9: 279-287, 2008.
2. Ohtsu A: Chemotherapy for metastatic gastric cancer: past, present and future. J Gastroenterol 43: 256-264, 2008.
3. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A and Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810-1820, 2007.
4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E and Buyse M: Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303: 1729-1737, 2010.
5. Sherr CJ: G1 phase progression: cycling on cue. Cell 79: 551-555, 1994.
6. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
7. Gao P, Zhou GY, Liu Y, Li JS, Zhen JH and Yuan YP: Alteration of cyclin D1 in gastric carcinoma and its clinicopathologic significance. World J Gastroenterol 10: 2936-2939, 2004.
8. Motokura T and Arnold A: Cyclin D and oncogenesis. Curr Opin Genet Dev 3: 5-10, 1993.
9. Coco Martin JM, Balkenende A, Verschoor T, Lallemand F and Michalides R: Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 59: 1134-1140, 1999.
10. Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W and Weinstein IB: Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth and enhances apoptosis. Cell Growth Differ 7: 699-710, 1996.
11. Kuroda Y, Sakai A, Tsuyama N, Katayama Y, Munemasa S, Asaoku H, Okikawa Y, Nakaju N, Mizuno M, Ogawa K, Nishisaka T, Matsui H, Tanaka H and Kimura A: Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma. Int J Oncol 33: 1201-1213, 2008.
12. Kornmann M, Arber N and Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352, 1998.
13. Warenius HM, Seabra LA and Maw P: Sensitivity to cis- diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not C-RAF-1 protein. Int J Cancer 67: 224-231, 1996.
14. Simizu S, Shibasaki F and Osada H: Bcl-2 inhibits calcineurin-mediated Fas ligand expression in antitumor drug-treated baby hamster kidney cells. Jpn J Cancer Res 91: 706-714, 2000.
15. Zhou X, Zhang Z, Yang X, Chen W and Zhang P: Inhibition of cyclin D1 expression by cyclin D1 shRNAs in human oral squamous cell carcinoma cells is associated with increased cisplatin chemosensitivity. Int J Cancer 124: 483-489, 2009.
16. Sun Y, Luo D and Liao DJ: Cyclin D1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog 11: 12, 2012.
17. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282: 1318-1321, 1998.
18. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999.
19. Curnock AP, Logan MK and Ward SG: Chemokine signalling: pivoting around multiple phosphoinositide 3-kinases. Immunology 105: 125-136, 2002.
20. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.
21. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85, 1999.
22. Wang C-Y, Mayo MW and Baldwin AS: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 274: 784-787, 1996.
23. Camp ER, Li J, Minnich DJ, Brank A, Moldawer LL, MacKay SL and Hochwald SN: Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J Am Coll Surg 199: 249-258, 2004.
24. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML and Cheng AL: Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-κB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. J Endocrinol 188: 311-319, 2006.
25. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S and Herlyn M: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 59: 4876-4881, 1999.
26. Huang WS, Wang JP, Wang T, Fang JY, Lan P and Ma JP: ShRNA-mediated gene silencing of beta-catenin inhibits growth of human colon cancer cells. World J Gastroenterol 13: 6581-6587, 2007.
27. Liang CC, Park AY and Guan JL: In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333, 2007.
28. Tiang JM, Butcher NJ and Minchin RF: Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun 393: 95-100, 2010.
29. Pearson G, English JM, White MA and Cobb MH: ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation. J Biol Chem 276: 7927-7931, 2001.
30. Martin V, Herrera F, Carrera-Gonzalez P, Garcia-Santos G, Antolin I, Rodriguez-Blanco J and Rodriguez C: Intracellular signaling pathways involved in the cell growth inhibition of glioma cells by melatonin. Cancer Res 66: 1081-1088, 2006.
31. Cheng JC, Chou CH, Kuo ML and Hsieh CY: Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009-7018, 2006.
32. Shin JY, Kim JO, Lee SK, Chae HS and Kang JH: LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 10: 425, 2010.
33. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS and Lee JS: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13: 1893-1898, 2002.
34. Song M, Zhang R, Dai Y, Gao F, Chi H, Lv G, Chen B and Wang X: The in vitro inhibition of multidrug resistance by combined nanoparticulate titanium dioxide and UV irradition. Biomaterials 27: 4230-4238, 2006.
35. Yoshida K and Toge T: Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer. Gan To Kagaku Ryoho 31: 1982-1986, 2004.
36. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR and Schafer H: Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 22: 3243-3251, 2003.
37. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447, 2004.
38. Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV and Korc M: Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res 59: 3505-3511, 1999.
39. Zhou H, Fujigaki Y, Kato A, Miyaji T, Yasuda H, Tsuji T, Yamamoto T, Yonemura K and Hishida A: Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats. Am J Physiol Renal Physiol 291: F225-F235, 2006.
40. Liu N, Zhang J, Zhang J, Liu S, Liu Y and Zheng D: Erbin-regulated sensitivity of MCF-7 breast cancer cells to TRAIL via ErbB2/AKT/NF-kappaB pathway. J Biochem 143: 793-801, 2008.